As Biotechnology companies, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and ChemoCentryx Inc. (NASDAQ:CCXI) are our subject to compare. And more specifically their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioMarin Pharmaceutical Inc.||1.52B||9.71||89.53M||-0.50||0.00|
Table 1 demonstrates BioMarin Pharmaceutical Inc. and ChemoCentryx Inc.’s top-line revenue, earnings per share and valuation.
Table 2 hightlights the net margins, return on assets and return on equity of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|BioMarin Pharmaceutical Inc.||-5.89%||-3.1%||-2%|
Risk and Volatility
BioMarin Pharmaceutical Inc. is 47.00% more volatile than Standard and Poor’s 500 because the company has a beta of 1.47. Competitively, ChemoCentryx Inc. is 30.00% more volatile than Standard and Poor’s 500, because of the 1.3 beta.
3.8 and 2.8 are the respective Current Ratio and a Quick Ratio of BioMarin Pharmaceutical Inc. Its rival ChemoCentryx Inc.’s Current and Quick Ratios are 3.4 and 3.4 respectively. BioMarin Pharmaceutical Inc. has a better chance of clearing its pay short and long-term debts than ChemoCentryx Inc.
The following table shown below contains the ratings and recommendations for BioMarin Pharmaceutical Inc. and ChemoCentryx Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|BioMarin Pharmaceutical Inc.||0||4||8||2.67|
BioMarin Pharmaceutical Inc.’s upside potential currently stands at 39.28% and an $114.64 average target price. Competitively the average target price of ChemoCentryx Inc. is $22.25, which is potential 156.04% upside. Based on the analysts belief we can conclude, ChemoCentryx Inc. is looking more favorable than BioMarin Pharmaceutical Inc.
Institutional and Insider Ownership
Institutional investors held 0% of BioMarin Pharmaceutical Inc. shares and 52.8% of ChemoCentryx Inc. shares. BioMarin Pharmaceutical Inc.’s share held by insiders are 0.4%. Insiders Competitively, held 4.2% of ChemoCentryx Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|BioMarin Pharmaceutical Inc.||5.37%||-5.11%||-8.49%||-8.9%||-2.66%||2.36%|
For the past year BioMarin Pharmaceutical Inc. has weaker performance than ChemoCentryx Inc.
BioMarin Pharmaceutical Inc. beats ChemoCentryx Inc. on 7 of the 12 factors.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan (CCX168), an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis. It has a partnership with Vifor (International) Ltd. for the geographic commercial rights of Avacopan in Europe and other international markets. ChemoCentryx, Inc. was founded in 1997 and is headquartered in Mountain View, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.